Shares of Viking Therapeutics (VKTX) are moving lower in pre-market trading after Eli Lilly (LLY) announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Orforglipron is the first oral small molecule glucagon-like peptide-1 receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial, Lilly stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics’ VK2735: A Promising Contender Amidst Pfizer’s Setback
- Promising Pipeline and Strategic Developments Drive Buy Rating for Viking Therapeutics
- Viking Therapeutics’ VK2735 Gains Buy Rating Amid Pfizer’s GLP-1 Drug Halt and Promising Trial Results
- BTIG highlights some reasons to own Viking shares after danuglipron discontinued
- Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill